<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-22504" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Haloperidol</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rahman</surname>
            <given-names>Sajedur</given-names>
          </name>
          <aff>St. John's Episcopal Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Marwaha</surname>
            <given-names>Raman</given-names>
          </name>
          <aff>Case Western Reserve Un/MetroHealth MC</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sajedur Rahman declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Raman Marwaha declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>9</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-22504.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Haloperidol, a first-generation typical antipsychotic, is commonly used worldwide to block dopamine D2 receptors in the brain and exert its antipsychotic action.&#x000a0;The medication is used to manage the positive symptoms of schizophrenia, including hallucinations and delusions. Haloperidol has received approval from the U.S. Food and Drug Administration (FDA) for a wide array of clinical applications, while also exhibiting off-label uses.&#x000a0;The&#x000a0;FDA-approved indications for haloperidol include schizophrenia, Tourette syndrome, and severe behavioral disorders in children, characterized by combative and explosive hyperexcitability, as well as hyperactivity in children, characterized by impulsivity, attention difficulties, aggressiveness, mood fluctuations, and low frustration tolerance. This activity highlights the mechanism of action, administration, adverse event profile, toxicity, monitoring, and pertinent interactions relevant to interprofessional healthcare team members when using haloperidol effectively to manage diverse indications.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the FDA-approved indications for haloperidol, including schizophrenia, Tourette syndrome, and severe behavioral disorders in children.</p></list-item><list-item><p>Screen patients for contraindications, comorbidities, and potential drug interactions before initiating haloperidol therapy.</p></list-item><list-item><p>Implement appropriate dosing strategies based on patient characteristics, including age, weight, and underlying conditions.</p></list-item><list-item><p>Select haloperidol as a suitable antipsychotic option based on patient characteristics, medical history, and treatment goals.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22504&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22504">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-22504.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Haloperidol is a first-generation typical antipsychotic drug that is commonly used worldwide. The medication is considered a typical antipsychotic as it manages the positive symptoms of schizophrenia, including hallucinations and&#x000a0;delusions.<xref ref-type="bibr" rid="article-22504.r1">[1]</xref><xref ref-type="bibr" rid="article-22504.r2">[2]</xref></p>
        <p>Haloperidol has received approval from the U.S. Food and Drug Administration (FDA) for a wide array of clinical applications while also exhibiting off-label uses.</p>
        <p>
<bold>FDA-Approved&#x000a0;Indications</bold>
</p>
        <p>The FDA-approved indications for&#x000a0;haloperidol are listed below.</p>
        <p><bold>Schizophrenia:</bold>&#x000a0;According to the American Psychiatry Association guidelines, individuals with schizophrenia should possess a comprehensive and well-documented patient-centered treatment plan that aligns with evidence-based therapeutic approaches, and haloperidol may be a component of the plan.<xref ref-type="bibr" rid="article-22504.r3">[3]</xref><xref ref-type="bibr" rid="article-22504.r4">[4]</xref></p>
        <p><bold>Tourette syndrome:</bold>&#x000a0;Haloperidol is indicated to manage tics and vocal expressions in pediatric and adult populations.<xref ref-type="bibr" rid="article-22504.r5">[5]</xref></p>
        <p><bold>Severe behavioral disorders&#x000a0;in children:</bold>&#x000a0;Haloperidol effectively treats combative and explosive hyperexcitability, which is not attributable to immediate provocation. Haloperidol should be considered for use in children only after other psychotherapeutic and non-antipsychotic medications&#x000a0;have proven ineffective in producing a response.<xref ref-type="bibr" rid="article-22504.r6">[6]</xref></p>
        <p><bold>Hyperactivity in children:</bold>&#x000a0;Haloperidol exhibits effectiveness in children presenting with excessive motor activity and&#x000a0;conduct disorders&#x000a0;consisting of&#x000a0;symptoms, including impulsivity, attention difficulties, aggressiveness, mood fluctuations, and low frustration tolerance. Haloperidol should be considered for use in children only after other psychotherapeutic and non-antipsychotic medications&#x000a0;have proven ineffective.<xref ref-type="bibr" rid="article-22504.r7">[7]</xref></p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>The off-label uses of haloperidol&#x000a0;include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Agitation-associated with psychiatric disorders&#x000a0;<xref ref-type="bibr" rid="article-22504.r8">[8]</xref></p>
          </list-item>
          <list-item>
            <p>Acute mania&#x000a0;<xref ref-type="bibr" rid="article-22504.r9">[9]</xref></p>
          </list-item>
          <list-item>
            <p>Chemotherapy-induced nausea and vomiting&#x000a0;<xref ref-type="bibr" rid="article-22504.r10">[10]</xref></p>
          </list-item>
          <list-item>
            <p>Management of&#x000a0;intractable hiccups&#x000a0;<xref ref-type="bibr" rid="article-22504.r11">[11]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22504.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Haloperidol, a first-generation typical antipsychotic, exerts its antipsychotic effects by blocking dopamine D2 receptors in the brain. This drug reaches its maximum effectiveness when 72% of dopamine receptors are blocked.<xref ref-type="bibr" rid="article-22504.r12">[12]</xref> Haloperidol's effects are not limited to the D2 receptor, as it also exerts blocking action on noradrenergic, cholinergic, and histaminergic receptors. The blocking of these receptors is associated with various&#x000a0;adverse drug reactions.<xref ref-type="bibr" rid="article-22504.r13">[13]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold>&#x000a0;Haloperidol, a highly lipophilic drug, undergoes extensive metabolism, leading to substantial interindividual variability in its pharmacokinetics. The oral formulation of haloperidol exhibits a bioavailability ranging from 60% to 70%. The time to reach peak plasma concentration is around 2 to 6 hours after oral administration, 20 minutes after intramuscular (IM) administration, and 6 days following depot IM administration.</p>
        <p><bold>Distribution:</bold>&#x000a0;Approximately 89% to 93% of the drug binds to plasma proteins. The concentration of haloperidol in the brain is significantly higher than the serum concentrations.<xref ref-type="bibr" rid="article-22504.r14">[14]</xref></p>
        <p><bold>Metabolism:</bold> Haloperidol is metabolized&#x000a0;in the liver via sulfoxidation and oxidation pathways, with involvement from CYP3A4, CYP2D6, and minor CYP1A2 enzymes.<xref ref-type="bibr" rid="article-22504.r15">[15]</xref></p>
        <p><bold>Elimination:</bold>&#x000a0;Approximately 30% of haloperidol&#x000a0;is primarily excreted in the urine, and the genetic polymorphism of CYP2D6 can significantly influence the plasma concentrations of the drug.<xref ref-type="bibr" rid="article-22504.r16">[16]</xref><xref ref-type="bibr" rid="article-22504.r17">[17]</xref></p>
      </sec>
      <sec id="article-22504.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Dosage Forms and Strengths</bold>
</p>
        <p>Haloperidol is a widely used medication across several countries and is available in various formulations. Haloperidol is available in tablet form in strengths of 0.5 mg, 1 mg, 2 mg, 5 mg, and 10 mg, and in an oral concentrate of 2 mg/mL for oral administration.&#x000a0;A nasal spray formulation of haloperidol is also available. Haloperidol lactate is available in a short-acting parenteral solution of 5 mg/mL for IM injection. Haloperidol decanoate is offered as a depot preparation and should be administered using the Z track technique.&#x000a0;A 21-gauge needle is recommended for administering haloperidol decanoate, and the volume per injection should not exceed 3 mL.<xref ref-type="bibr" rid="article-22504.r12">[12]</xref>&#x000a0;Haloperidol lactate can be given intravenously off-label, but haloperidol decanoate should only be administered via IM injection.</p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p><bold>Psychosis:</bold> For psychosis, the oral and&#x000a0;IM&#x000a0; forms can be used. For&#x000a0;moderate symptomology, the recommended dosage ranges from 0.5 to 2 mg orally, administered 2 to 3 times daily. In certain resistant cases, haloperidol dosages of up to 30 mg/d might be required. Acute agitation can be rapidly controlled with 2 to 5 mg IM injections every 4 to 8 hours. The maximum recommended IM dosage should not exceed 20 mg/d.<xref ref-type="bibr" rid="article-22504.r18">[18]</xref></p>
        <p><bold>Schizophrenia:</bold>&#x000a0;For moderate symptoms linked to schizophrenia, the recommended dosing involves oral administration of 0.5 to 2 mg of haloperidol, taken 2 to 3 times a day. For severe symptoms, the prescribed dosage is 3 to 5 mg of haloperidol administered orally to patients 2 to 3 times a day.&#x000a0;The maximum recommended oral dosage should not exceed 100 mg/d. For managing acute agitation in patients with schizophrenia, a short-acting IM haloperidol lactate dosage of 2 to 5 mg can be administered every 4 to 8 hours. The maximum recommended dosage for IM haloperidol lactate should not exceed 20 mg/d. The typical initial dosage of depot preparation of haloperidol decanoate administered intramuscularly is 10 to 20 times higher than the previous oral dose.&#x000a0;The maximum recommended dosage of&#x000a0;IM haloperidol decanoate is&#x000a0;450 mg once every&#x000a0;4 weeks.<xref ref-type="bibr" rid="article-22504.r3">[3]</xref></p>
        <p><bold>Tourette syndrome:</bold>&#x000a0;As the product insert states, the weight-based haloperidol dosage ranges between&#x000a0;0.05&#x000a0;and 0.075 mg/kg/d.&#x000a0;According to the American Academy of Child and Adolescent Psychiatry guidelines, the usual starting dosage of haloperidol is 0.25 to 0.5 mg daily. The recommended maintenance dosage of haloperidol ranges from 1 to 4 mg daily, administered in 2 or 3 equally divided doses.<xref ref-type="bibr" rid="article-22504.r19">[19]</xref></p>
        <p><bold>Acute agitation (off-label use):&#x000a0;</bold>In cases of acute agitation, off-label dosing ranges from 0.5 to 10 mg orally, administered every 1 to 4 hours. The recommended maximum daily dosage for haloperidol is 100 mg, and it is advised to use the lowest effective dose.</p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:</bold>&#x000a0;Patients with impaired liver function may experience elevated haloperidol plasma levels due to decreased plasma protein binding. Although no specific dose recommendations exist, cautious administration is recommended.</p>
        <p><bold>Renal impairment:</bold>&#x000a0;Dosage adjustments of haloperidol are not required for patients with renal impairment.</p>
        <p><bold>Pediatric considerations:</bold>&#x000a0;Although haloperidol is no longer commonly used as the primary treatment for behavioral disorders, it might be essential in refractory or complex cases. The recommended dosing range for haloperidol is 0.05 to 0.075 mg/kg/d. Notably, haloperidol is listed in the Key Potentially Inappropriate Drugs in Pediatrics (KIDs)&#x000a0;List due to the heightened risk of extrapyramidal reactions, such as acute dystonia.<xref ref-type="bibr" rid="article-22504.r20">[20]</xref></p>
        <p><bold>Older patients:</bold>&#x000a0;Haloperidol is classified as a high-risk medication according to the American Geriatrics Society Beers Criteria, underscoring the importance of using the lowest effective dose for the shortest feasible duration.<xref ref-type="bibr" rid="article-22504.r21">[21]</xref></p>
        <p><bold>Pregnancy considerations:</bold>&#x000a0;No well-controlled studies have been conducted regarding haloperidol use in pregnant women. However, reports suggest that newborns of mothers who took haloperidol may have limb malformations, although a causal link has not been definitively established. As these experiences do not definitively rule out the potential for a fetal anomaly caused by haloperidol, this drug should be considered only if the benefits outweigh the potential risks to the fetus.<xref ref-type="bibr" rid="article-22504.r22">[22]</xref></p>
        <p><bold>Breastfeeding considerations:</bold>&#x000a0;Reports suggest that haloperidol can cause galactorrhea due to hyperprolactinemia as an adverse effect.&#x000a0;Haloperidol's blocking of dopamine receptors in the tuberoinfundibular pathway leads to hyperprolactinemia.<bold><bold>&#x000a0;</bold></bold>As haloperidol is excreted in human breast milk, lactating women on haloperidol should refrain from nursing their infants.[<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK500910/">20</ext-link>]</p>
      </sec>
      <sec id="article-22504.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Typical antipsychotic medications, such as haloperidol, are associated with extrapyramidal symptoms due to their blockade of the dopamine pathway in the brain.<xref ref-type="bibr" rid="article-22504.r6">[6]</xref></p>
        <p>
<bold>Extrapyramidal&#x000a0;Adverse Effects</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Acute dystonia:</bold>&#x000a0;This condition&#x000a0;develops within hours to days of initiation and may manifest as muscle spasms, stiffness, or even oculogyric crisis.</p>
          </list-item>
          <list-item>
            <p><bold>Akathisia: </bold>This syndrome manifests within days to months of haloperidol usage and is characterized by a sensation of restlessness.</p>
          </list-item>
          <list-item>
            <p><bold>Neuroleptic malignant syndrome (NMS):&#x000a0;</bold>Although uncommon, this severe condition can manifest as high fever and muscle rigidity.</p>
          </list-item>
          <list-item>
            <p><bold>Parkinsonism:</bold>&#x000a0;This condition emerges after days to months of haloperidol usage.</p>
          </list-item>
          <list-item>
            <p><bold>Tardive dyskinesia (TD):</bold>&#x000a0;TD emerges after several years and is characterized by choreiform movements, particularly in the orofacial region.<xref ref-type="bibr" rid="article-22504.r23">[23]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Common&#x000a0;<bold>Adverse Effects</bold></bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Anticholinergic effects<bold>&#x000a0;</bold>include increased body temperature, dry mouth, drowsiness or sedation, constipation, and urinary retention.</p>
          </list-item>
          <list-item>
            <p>Other common adverse effects of haloperidol include sedation, weight gain, erectile dysfunction in males, and oligomenorrhea or amenorrhea in females.</p>
          </list-item>
        </list>
        <p>
<bold>Less Common&#x000a0;<bold>Adverse Effects</bold></bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Orthostatic hypotension:</bold>&#x000a0;Following IM injection of haloperidol, symptoms may encompass tachycardia and palpitations.</p>
          </list-item>
          <list-item>
            <p><bold>Lens opacities:</bold>&#x000a0;This eye complication occurs with prolonged usage of the drug.</p>
          </list-item>
          <list-item>
            <p>Other&#x000a0;infrequent adverse effects of&#x000a0;haloperidol include agitation, generalized anxiety, cerebral edema, new-onset depression, dizziness, euphoric mood, headache, sleeplessness, poikilothermia, restlessness, generalized weakness, confusion, anorexia, constipation, dyspepsia, ileus, and decreased gag reflex.</p>
          </list-item>
        </list>
        <p>
<bold>Uncommon&#x000a0;<bold>Adverse Effects</bold></bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Electrocardiogram (ECG) changes:</bold>&#x000a0;ECG changes related to haloperidol usage may involve QT prolongation and torsades de pointes.<xref ref-type="bibr" rid="article-22504.r24">[24]</xref></p>
          </list-item>
          <list-item>
            <p>Other uncommon adverse effects include&#x000a0;photosensitivity reactions, generalized pruritus, diarrhea, gastrointestinal distress, blood dyscrasia, and ejaculatory&#x000a0;problems.</p>
          </list-item>
        </list>
        <p>
<bold>Rare&#x000a0;<bold>Adverse Effects</bold></bold>
</p>
        <p>Rarely occurring symptoms associated with haloperidol include cholestatic jaundice, priapism, inflammation and nodule formations with haloperidol decanoate use, and seizures.<xref ref-type="bibr" rid="article-22504.r25">[25]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p><bold>CYP3A4 and CYP2D6 inhibitors:</bold>&#x000a0;Coadministration of haloperidol with CYP3A4 and CYP2D6 inhibitors leads to elevated haloperidol plasma concentration levels and subsequent heightened adverse reactions. Therefore, it is advisable to monitor patients concurrently using these medications closely. If signs and symptoms indicative of amplified haloperidol pharmacological effects arise, haloperidol dose should be reduced as necessary based on clinical judgment.</p>
        <list list-type="bullet">
          <list-item>
            <p>CYP3A4 inhibitors:&#x000a0;CYP3A4 inhibitors include alprazolam, ketoconazole, itraconazole, ritonavir, and nefazodone.</p>
          </list-item>
          <list-item>
            <p>CYP2D6 inhibitors:&#x000a0;CYP2D6 inhibitors include chlorpromazine, promethazine, paroxetine, quinidine, sertraline, and venlafaxine.</p>
          </list-item>
          <list-item>
            <p>CYP3A4 and CYP2D6 inhibitors: CYP3A4 and CYP2D6 inhibitors include&#x000a0;fluvoxamine, fluoxetine, and ritonavir.</p>
          </list-item>
        </list>
        <p><bold>Metabolic inhibitors:</bold>&#x000a0;An increase in&#x000a0;the QTc interval was observed when haloperidol was coadministered with the metabolic inhibitors, including paroxetine at a dosage of 20 mg/d and ketoconazole at 400 mg/d.</p>
        <p><bold>CYP3A4 inducers:</bold>&#x000a0;When potent enzyme inducers of CYP3A4, such as carbamazepine, phenobarbital, phenytoin, rifampin, and St John's wort, are coadministered with haloperidol, there is a potential for a gradual reduction in haloperidol serum concentrations, which may subsequently diminish the drug's efficacy. Under such circumstances, vigilant patient monitoring is essential, with the possibility of adjusting the haloperidol dosage as needed. Furthermore, after discontinuing the CYP3A4 inducer treatment, there is a potential for gradual elevation in haloperidol concentration. Hence, it might be necessary to consider reducing the dosage or modifying the dosing interval for haloperidol.</p>
        <p><bold>Effects of haloperidol on other drugs:</bold>&#x000a0;When haloperidol is coadministered&#x000a0;with tricyclic antidepressants, such as desipramine or imipramine, it may increase plasma concentration levels due to its inhibitory effect on the CYP2D6 enzyme.</p>
        <p><bold>Lithium:</bold>&#x000a0;The simultaneous use of lithium and haloperidol has been associated with reported cases of encephalopathy stemming from lithium neurotoxicity. Hence, it is&#x000a0;advisable to closely monitor for signs and symptoms of neurological toxicity in patients in such cases.<xref ref-type="bibr" rid="article-22504.r26">[26]</xref></p>
      </sec>
      <sec id="article-22504.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Haloperidol is contraindicated in cases of documented hypersensitivity to the drug, as instances of angioedema have been reported.<xref ref-type="bibr" rid="article-22504.r27">[27]</xref><xref ref-type="bibr" rid="article-22504.r28">[28]</xref><xref ref-type="bibr" rid="article-22504.r29">[29]</xref> Haloperidol is also contraindicated in patients diagnosed with Parkinson disease and dementia with Lewy bodies, those who are comatose, and in individuals with conditions marked by a significantly depressed central nervous system (CNS). As&#x000a0;numerous drugs, including barbiturates, benzodiazepines, and opioids, can induce CNS depression, the concurrent use of haloperidol should be either avoided or approached with extreme caution.<xref ref-type="bibr" rid="article-22504.r12">[12]</xref><xref ref-type="bibr" rid="article-22504.r27">[27]</xref></p>
        <p>
<bold>Box Warning</bold>
</p>
        <p>Older patients with dementia-related psychosis have an elevated mortality risk of approximately 1.6 to 1.7 times higher than other patients. Across 17 placebo-controlled trials lasting 10 weeks, patients using atypical antipsychotics had a 4.5% death rate compared to 2.6% for the placebo group. Hence, it is noteworthy that the FDA disapproves haloperidol for treating patients with dementia-related psychosis.<xref ref-type="bibr" rid="article-22504.r30">[30]</xref></p>
        <p>
<bold>Warnings and Precautions</bold>
</p>
        <p>Haloperidol should not be used as a chemical restraint to address patient behavior or restrict patient mobility, as it is not a conventional or accepted treatment. This approach should be reserved for situations where the need to address potential violence is crucial to ensure the safety of both staff and patients.<xref ref-type="bibr" rid="article-22504.r31">[31]</xref></p>
        <p>
<bold>Cardiovascular effects</bold>
</p>
        <p>Administering haloperidol intravenously or exceeding the recommended doses of any haloperidol formulation is linked to an increased risk of QTc interval prolongation, torsades de pointes, and sudden death. Patients with electrolyte imbalances, particularly hypokalemia or hypomagnesemia, hypothyroidism, preexisting cardiac abnormalities, familial history of long QT syndrome, or those concurrently taking drugs known to prolong QTc interval require special attention and caution.<xref ref-type="bibr" rid="article-22504.r32">[32]</xref><xref ref-type="bibr" rid="article-22504.r33">[33]</xref></p>
        <p>
<bold>Cerebrovascular adverse reactions</bold>
</p>
        <p>Antipsychotic use is associated with an increased risk of transient ischemic attack, stroke, and mortality, particularly in older patients with dementia-related psychosis. As a result, it is crucial to exercise caution when dealing with patients at a higher risk for cerebrovascular adverse reactions.<xref ref-type="bibr" rid="article-22504.r34">[34]</xref></p>
        <p>
<bold><bold>Tardive dyskinesia (</bold>TD)</bold>
</p>
        <p>TD is characterized by involuntary, irreversible, and dyskinetic movements that can arise in patients receiving antipsychotic medications. This risk is most pronounced among older women. The likelihood of developing irreversible TD is directly proportional to the duration of treatment and the total cumulative dose of antipsychotic medication. Although rarely, TD can develop even after relatively short treatment periods and low doses. Therefore, antipsychotic drugs, including haloperidol, should be prescribed in a manner that optimally reduces the risk of TD occurrence.</p>
        <p>Chronic antipsychotic medicines should primarily be considered for patients with chronic illnesses responsive to such treatments.&#x000a0;In addition, these medications should be considered for patients who lack access to alternative or equally effective, potentially less toxic treatments. When chronic treatment is necessary, clinicians should recommend using the smallest effective dose and the shortest feasible treatment duration that achieves a reasonable clinical response.</p>
        <p>Healthcare providers should periodically reevaluate the necessity of ongoing treatment, and if any indications of TD become apparent, they may contemplate discontinuing haloperidol or transitioning to atypical antipsychotics.&#x000a0;In refractory cases of TD, vesicular monoamine transporter type-2 (VMAT2) inhibitors, such as deutetrabenazine and valbenazine, can be considered therapeutic options.<xref ref-type="bibr" rid="article-22504.r35">[35]</xref><xref ref-type="bibr" rid="article-22504.r36">[36]</xref></p>
        <p>
<bold><bold>Neuroleptic malignant syndrome (</bold>NMS)</bold>
</p>
        <p>NMS is clinically characterized by muscle rigidity, hyperpyrexia, altered mental status, including catatonic signs, and indications of autonomic instability such as tachycardia, irregular pulse or blood pressure, diaphoresis, and cardiac arrhythmias. Furthermore, patients might present with elevated creatine phosphokinase, myoglobinuria, rhabdomyolysis, or acute renal failure. The management of NMS requires promptly discontinuing antipsychotic drugs and non-essential medications, providing symptomatic care, closely monitoring patients, and addressing significant medical concerns with specific treatments.</p>
        <p>If a patient requires antipsychotic medicine treatment after recovery from NMS, the potential reintroduction of haloperidol should be approached with careful consideration and caution. The patient should undergo vigilant monitoring, as NMS recurrences have been documented. In addition,&#x000a0;heatstroke and hyperpyrexia cases that are not directly linked to NMS have also been reported concerning haloperidol use.<xref ref-type="bibr" rid="article-22504.r23">[23]</xref></p>
        <p>
<bold>Falls</bold>
</p>
        <p>Antipsychotics, including haloperidol, have been associated with somnolence, motor instability, and orthostatic hypotension, all of which can contribute to falls, fractures, and other fall-related injuries. For older adults with conditions or medications that could exacerbate these effects, the risk of falls must be assessed at the initiation of antipsychotic treatment and throughout the treatment duration.<xref ref-type="bibr" rid="article-22504.r37">[37]</xref></p>
        <p>
<bold>Leukopenia/neutropenia/agranulocytosis</bold>
</p>
        <p>Postmarketing surveillance has identified leukopenia and neutropenia linked to haloperidol usage. Continuous monitoring of complete blood count with differential is recommended. Haloperidol should be&#x000a0;discontinued if there is a reduction in white blood cells and absolute neutrophil count.<xref ref-type="bibr" rid="article-22504.r38">[38]</xref><xref ref-type="bibr" rid="article-22504.r39">[39]</xref></p>
      </sec>
      <sec id="article-22504.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Monitoring of patients is crucial due to the possibility of adverse drug reactions, particularly when haloperidol is administered in the IM form. Consensus guidelines for therapeutic drug monitoring (TDM) recommend a serum therapeutic range of 1 to 10 ng/mL for haloperidol. Serum levels exceeding 15 ng/mL can elevate the risk of toxicity. Ideally, dose titration hinges on clinical response and the emergence of adverse effects. Nevertheless, TDM proves valuable when poor compliance is suspected.<xref ref-type="bibr" rid="article-22504.r15">[15]</xref> Clinicians should monitor haloperidol blood levels in patients at 12- or 24-hour intervals or after administering the last dose of haloperidol.<xref ref-type="bibr" rid="article-22504.r40">[40]</xref></p>
      </sec>
      <sec id="article-22504.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Toxicities are the exaggerated symptoms of known pharmacological effects and adverse drug reactions. The most prominent toxicities of haloperidol are severe extrapyramidal symptoms, hypotension, and sedation. The patient may appear comatose with severe respiratory depression or shock from hypotension. The extrapyramidal symptoms include akathisia, rigidity, bradykinesia, tremor, and acute dystonia. Haloperidol overdose can cause torsades de pointes, a type of ECG change that leads to arrhythmia or cardiac arrest.<xref ref-type="bibr" rid="article-22504.r24">[24]</xref></p>
        <p>As no specific antidote exists, supportive treatment is the mainstay of haloperidol toxicity. If a patient shows signs of toxicity, the clinician should promptly consider performing gastric lavage or emesis induction on the patient, followed by administering activated charcoal. Maintaining the airway, breathing, and circulation are critical for survival. An oropharyngeal airway or an endotracheal tube can help maintain an unobstructed airway.</p>
        <p>Patients in a comatose state with difficulty breathing or an obstruction in their upper airway often require a tracheostomy. Nasal prongs or facemasks are used to administer supplemental oxygen. Patients with&#x000a0;refractory&#x000a0;hypoxia often require intubation and mechanical ventilation. Hypotension and circulatory collapse&#x000a0;require aggressive treatment with intravenous fluids, concentrated albumin, and vasopressor agents, such as norepinephrine or phenylephrine. Epinephrine should not be used as it can decrease patients' blood pressure levels.&#x000a0;</p>
        <p>Benztropine is used to treat extrapyramidal reactions, including acute dystonia.<xref ref-type="bibr" rid="article-22504.r41">[41]</xref>&#x000a0;Propranolol and anticholinergics are used for managing akathisia.<xref ref-type="bibr" rid="article-22504.r42">[42]</xref> ECG and vital signs require regular monitoring, especially for&#x000a0;signs of torsades de pointes, QT prolongation, or dysrhythmias. Cardiac monitoring should be continued until the ECG returns to normal. If the patient experiences arrhythmias, which could be life-threatening, prompt management of the condition with appropriate anti-arrhythmic measures should be initiated.<xref ref-type="bibr" rid="article-22504.r43">[43]</xref></p>
      </sec>
      <sec id="article-22504.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Although haloperidol is a widely used antipsychotic medication, it can cause various adverse effects and toxicities. As a result, healthcare professionals must be&#x000a0;familiar with the drug's pharmacology, recognize the signs of toxicity, and know how to manage any adverse effects that may arise while using the medicine. Therefore,&#x000a0;a&#x000a0;proper history and physical examination are necessary before initiating haloperidol in patients.</p>
        <p>The recommended&#x000a0;approach&#x000a0;for prescribing or ordering haloperidol is as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Healthcare providers, including physicians and advanced practice practitioners, should prescribe haloperidol for suitable indications.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Psychiatrists are responsible for the comprehensive&#x000a0;care of patients undergoing haloperidol therapy.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Pharmacists are critical in ensuring proper patient dosing and notifying clinicians of potential drug interactions.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Nurses specializing in this domain should thoroughly review medication administration records to prevent any potential administration errors.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Emergency department physicians and triage nurses are the primary responders in the event of an acute haloperidol overdose.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Intensivists are&#x000a0;responsible for ensuring appropriate ICU care and vigilant monitoring of patients during their hospital stay.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>In severe haloperidol toxicity, seeking consultation from a medical toxicologist is recommended.</p>
          </list-item>
        </list>
        <p>The American Psychiatric Association guidelines recommend that individuals with schizophrenia experiencing their initial episode of psychosis should receive care within a coordinated specialty care program.<xref ref-type="bibr" rid="article-22504.r3">[3]</xref> Effective interprofessional coordination through shared decision-making among physicians, advanced practice practitioners, nurses, specialists, pharmacists, and other healthcare providers is essential to enhance patient outcomes and minimize or eradicate adverse events associated with haloperidol therapy. The above-illustrated interprofessional healthcare team approach enhances the efficacy of haloperidol therapy, resulting in reduced adverse events and improved patient outcomes.&#x000a0;</p>
      </sec>
      <sec id="article-22504.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22504&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22504">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/22504/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=22504">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-22504.s11">
        <title>References</title>
        <ref id="article-22504.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>L&#x000f3;pez-Mu&#x000f1;oz</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Alamo</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>The consolidation of neuroleptic therapy: Janssen, the discovery of haloperidol and its introduction into clinical practice.</article-title>
            <source>Brain Res Bull</source>
            <year>2009</year>
            <month>Apr</month>
            <day>29</day>
            <volume>79</volume>
            <issue>2</issue>
            <fpage>130</fpage>
            <page-range>130-41</page-range>
            <pub-id pub-id-type="pmid">19186209</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22504.r2">
          <label>2</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>McDonagh</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Dana</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Selph</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Devine</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Cantor</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bougatsos</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Blazina</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Grusing</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kopelovich</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Monroe-DeVita</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Haupt</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <source>Treatments for Schizophrenia in Adults: A Systematic Review [Internet]</source>
            <publisher-name>Agency for Healthcare Research and Quality (US)</publisher-name>
            <publisher-loc>Rockville (MD)</publisher-loc>
            <year>2017</year>
            <month>10</month>
            <pub-id pub-id-type="pmid">29537779</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22504.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Keepers</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Fochtmann</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Anzia</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Benjamin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lyness</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Mojtabai</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Servis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Walaszek</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Buckley</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lenzenweger</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Degenhardt</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>SH</given-names>
              </name>
              <collab>(Systematic Review)</collab>
            </person-group>
            <article-title>The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia.</article-title>
            <source>Am J Psychiatry</source>
            <year>2020</year>
            <month>Sep</month>
            <day>01</day>
            <volume>177</volume>
            <issue>9</issue>
            <fpage>868</fpage>
            <page-range>868-872</page-range>
            <pub-id pub-id-type="pmid">32867516</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22504.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kishi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ikuta</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sakuma</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Okuya</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Iwata</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of antipsychotic treatments for schizophrenia: A systematic review and network meta-analysis of randomized trials in Japan.</article-title>
            <source>J Psychiatr Res</source>
            <year>2021</year>
            <month>Jun</month>
            <volume>138</volume>
            <fpage>444</fpage>
            <page-range>444-452</page-range>
            <pub-id pub-id-type="pmid">33964682</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22504.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Besag</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Vasey</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Lao</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Chowdhury</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Stern</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Pharmacological treatment for Tourette syndrome in children and adults: What is the quality of the evidence? A systematic review.</article-title>
            <source>J Psychopharmacol</source>
            <year>2021</year>
            <month>Sep</month>
            <volume>35</volume>
            <issue>9</issue>
            <fpage>1037</fpage>
            <page-range>1037-1061</page-range>
            <pub-id pub-id-type="pmid">34286606</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22504.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dold</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Samara</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tardy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Leucht</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2015</year>
            <month>Jan</month>
            <day>16</day>
            <volume>1</volume>
            <issue>1</issue>
            <fpage>CD009831</fpage>
            <pub-id pub-id-type="pmid">25592299</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22504.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pringsheim</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hirsch</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gardner</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gorman</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 2: antipsychotics and traditional mood stabilizers.</article-title>
            <source>Can J Psychiatry</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>60</volume>
            <issue>2</issue>
            <fpage>52</fpage>
            <page-range>52-61</page-range>
            <pub-id pub-id-type="pmid">25886656</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22504.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ostinelli</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Brooke-Powney</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Adams</surname>
                <given-names>CE</given-names>
              </name>
            </person-group>
            <article-title>Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation).</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2017</year>
            <month>Jul</month>
            <day>31</day>
            <volume>7</volume>
            <issue>7</issue>
            <fpage>CD009377</fpage>
            <pub-id pub-id-type="pmid">28758203</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22504.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pacchiarotti</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Anmella</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Colomer</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Vieta</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>How to treat mania.</article-title>
            <source>Acta Psychiatr Scand</source>
            <year>2020</year>
            <month>Sep</month>
            <volume>142</volume>
            <issue>3</issue>
            <fpage>173</fpage>
            <page-range>173-192</page-range>
            <pub-id pub-id-type="pmid">33460070</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22504.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lohr</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Chemotherapy-induced nausea and vomiting.</article-title>
            <source>Cancer J</source>
            <year>2008</year>
            <season>Mar-Apr</season>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>85</fpage>
            <page-range>85-93</page-range>
            <pub-id pub-id-type="pmid">18391612</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22504.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moretto</surname>
                <given-names>EN</given-names>
              </name>
              <name>
                <surname>Wee</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wiffen</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Murchison</surname>
                <given-names>AG</given-names>
              </name>
            </person-group>
            <article-title>Interventions for treating persistent and intractable hiccups in adults.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2013</year>
            <month>Jan</month>
            <day>31</day>
            <volume>2013</volume>
            <issue>1</issue>
            <fpage>CD008768</fpage>
            <pub-id pub-id-type="pmid">23440833</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22504.r12">
          <label>12</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Chokhawala</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Stevens</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <chapter-title>Antipsychotic Medications</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>2</month>
            <day>26</day>
            <pub-id pub-id-type="pmid">30137788</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22504.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gao</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kemp</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Ganocy</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Gajwani</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Xia</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Calabrese</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review.</article-title>
            <source>J Clin Psychopharmacol</source>
            <year>2008</year>
            <month>Apr</month>
            <volume>28</volume>
            <issue>2</issue>
            <fpage>203</fpage>
            <page-range>203-9</page-range>
            <pub-id pub-id-type="pmid">18344731</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22504.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kornhuber</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wiltfang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Riederer</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bleich</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Neuroleptic drugs in the human brain: clinical impact of persistence and region-specific distribution.</article-title>
            <source>Eur Arch Psychiatry Clin Neurosci</source>
            <year>2006</year>
            <month>Aug</month>
            <volume>256</volume>
            <issue>5</issue>
            <fpage>274</fpage>
            <page-range>274-80</page-range>
            <pub-id pub-id-type="pmid">16788768</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22504.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hiemke</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bergemann</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Clement</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Conca</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Deckert</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Domschke</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Eckermann</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Egberts</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gerlach</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Greiner</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gr&#x000fc;nder</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Haen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Havemann-Reinecke</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Hefner</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Helmer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Janssen</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Jaquenoud</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Laux</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Messer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>M&#x000f6;ssner</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Paulzen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pfuhlmann</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Riederer</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Saria</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schoppek</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Schoretsanitis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Schwarz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gracia</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Stegmann</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Steimer</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Stingl</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Uhr</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ulrich</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Unterecker</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Waschgler</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zernig</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zurek</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Baumann</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017.</article-title>
            <source>Pharmacopsychiatry</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>51</volume>
            <issue>1-02</issue>
            <fpage>9</fpage>
            <page-range>9-62</page-range>
            <pub-id pub-id-type="pmid">28910830</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22504.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pouget</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Shams</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Tiwari</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Pharmacogenetics and outcome with antipsychotic drugs.</article-title>
            <source>Dialogues Clin Neurosci</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>16</volume>
            <issue>4</issue>
            <fpage>555</fpage>
            <page-range>555-66</page-range>
            <pub-id pub-id-type="pmid">25733959</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22504.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Milosavljevic</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bukvic</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Pavlovic</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Miljevic</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pe&#x00161;ic</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Molden</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ingelman-Sundberg</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Leucht</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jukic</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure: A Systematic Review and Meta-analysis.</article-title>
            <source>JAMA Psychiatry</source>
            <year>2021</year>
            <month>Mar</month>
            <day>01</day>
            <volume>78</volume>
            <issue>3</issue>
            <fpage>270</fpage>
            <page-range>270-280</page-range>
            <pub-id pub-id-type="pmid">33237321</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22504.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khushu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Powney</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Haloperidol for long-term aggression in psychosis.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2016</year>
            <month>Nov</month>
            <day>27</day>
            <volume>11</volume>
            <issue>11</issue>
            <fpage>CD009830</fpage>
            <pub-id pub-id-type="pmid">27889922</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22504.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murphy</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Lewin</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Storch</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Stock</surname>
                <given-names>S</given-names>
              </name>
              <collab>American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Quality Issues (CQI)</collab>
            </person-group>
            <article-title>Practice parameter for the assessment and treatment of children and adolescents with tic disorders.</article-title>
            <source>J Am Acad Child Adolesc Psychiatry</source>
            <year>2013</year>
            <month>Dec</month>
            <volume>52</volume>
            <issue>12</issue>
            <fpage>1341</fpage>
            <page-range>1341-59</page-range>
            <pub-id pub-id-type="pmid">24290467</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22504.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meyers</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Thackray</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Matson</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>McPherson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lubsch</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hellinga</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Hoff</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title><italic>K</italic>ey Potentially <italic>I</italic>nappropriate <italic>D</italic>rugs in Pediatrics: The KIDs List.</article-title>
            <source>J Pediatr Pharmacol Ther</source>
            <year>2020</year>
            <volume>25</volume>
            <issue>3</issue>
            <fpage>175</fpage>
            <page-range>175-191</page-range>
            <pub-id pub-id-type="pmid">32265601</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22504.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <collab>American Geriatrics Society 2012 Beers Criteria Update Expert Panel</collab>
            <article-title>American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults.</article-title>
            <source>J Am Geriatr Soc</source>
            <year>2012</year>
            <month>Apr</month>
            <volume>60</volume>
            <issue>4</issue>
            <fpage>616</fpage>
            <page-range>616-31</page-range>
            <pub-id pub-id-type="pmid">22376048</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22504.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Einarson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Boskovic</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Use and safety of antipsychotic drugs during pregnancy.</article-title>
            <source>J Psychiatr Pract</source>
            <year>2009</year>
            <month>May</month>
            <volume>15</volume>
            <issue>3</issue>
            <fpage>183</fpage>
            <page-range>183-92</page-range>
            <pub-id pub-id-type="pmid">19461391</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22504.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Battaglia</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Pharmacological management of acute agitation.</article-title>
            <source>Drugs</source>
            <year>2005</year>
            <volume>65</volume>
            <issue>9</issue>
            <fpage>1207</fpage>
            <page-range>1207-22</page-range>
            <pub-id pub-id-type="pmid">15916448</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22504.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beach</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Celano</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Sugrue</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Adams</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ackerman</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Noseworthy</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Huffman</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>QT Prolongation, Torsades de Pointes, and Psychotropic Medications: A 5-Year Update.</article-title>
            <source>Psychosomatics</source>
            <year>2018</year>
            <season>Mar-Apr</season>
            <volume>59</volume>
            <issue>2</issue>
            <fpage>105</fpage>
            <page-range>105-122</page-range>
            <pub-id pub-id-type="pmid">29275963</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22504.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pisani</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Oteri</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Costa</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Di Raimondo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Di Perri</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Effects of psychotropic drugs on seizure threshold.</article-title>
            <source>Drug Saf</source>
            <year>2002</year>
            <volume>25</volume>
            <issue>2</issue>
            <fpage>91</fpage>
            <page-range>91-110</page-range>
            <pub-id pub-id-type="pmid">11888352</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22504.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Netto</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Phutane</surname>
                <given-names>VH</given-names>
              </name>
            </person-group>
            <article-title>Reversible lithium neurotoxicity: review of the literatur.</article-title>
            <source>Prim Care Companion CNS Disord</source>
            <year>2012</year>
            <volume>14</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">22690368</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22504.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kahlon</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chirurgi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Worku Hassen</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Angioneurotic edema associated with haloperidol.</article-title>
            <source>Case Rep Emerg Med</source>
            <year>2012</year>
            <volume>2012</volume>
            <fpage>725461</fpage>
            <pub-id pub-id-type="pmid">23326722</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22504.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Strain</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Angioedema of the tongue due to haloperidol.</article-title>
            <source>Am J Emerg Med</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>53</volume>
            <fpage>284.e5</fpage>
            <page-range>284.e5-284.e6</page-range>
            <pub-id pub-id-type="pmid">34620528</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22504.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Masiran</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Persistent oromandibular dystonia and angioedema secondary to haloperidol.</article-title>
            <source>BMJ Case Rep</source>
            <year>2017</year>
            <month>Oct</month>
            <day>04</day>
            <volume>2017</volume>
            <pub-id pub-id-type="pmid">28978587</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22504.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jeste</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Blazer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Meeks</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Salzman</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tariot</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Yaffe</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>ACNP White Paper: update on use of antipsychotic drugs in elderly persons with dementia.</article-title>
            <source>Neuropsychopharmacology</source>
            <year>2008</year>
            <month>Apr</month>
            <volume>33</volume>
            <issue>5</issue>
            <fpage>957</fpage>
            <page-range>957-70</page-range>
            <pub-id pub-id-type="pmid">17637610</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22504.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Muir-Cochrane</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Oster</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gerace</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dawson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Damarell</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Grimmer</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>The effectiveness of chemical restraint in managing acute agitation and aggression: A systematic review of randomized controlled trials.</article-title>
            <source>Int J Ment Health Nurs</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>29</volume>
            <issue>2</issue>
            <fpage>110</fpage>
            <page-range>110-126</page-range>
            <pub-id pub-id-type="pmid">31498960</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22504.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beach</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Celano</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Noseworthy</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Januzzi</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Huffman</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>QTc prolongation, torsades de pointes, and psychotropic medications.</article-title>
            <source>Psychosomatics</source>
            <year>2013</year>
            <season>Jan-Feb</season>
            <volume>54</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-13</page-range>
            <pub-id pub-id-type="pmid">23295003</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22504.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meyer-Massetti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Sharpe</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Meier</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Guglielmo</surname>
                <given-names>BJ</given-names>
              </name>
            </person-group>
            <article-title>The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond?</article-title>
            <source>J Hosp Med</source>
            <year>2010</year>
            <month>Apr</month>
            <volume>5</volume>
            <issue>4</issue>
            <fpage>E8</fpage>
            <page-range>E8-16</page-range>
            <pub-id pub-id-type="pmid">20394022</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22504.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Langballe</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Engdahl</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Nordeng</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ballard</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Aarsland</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Selb&#x000e6;k</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Short- and long-term mortality risk associated with the use of antipsychotics among 26,940 dementia outpatients: a population-based study.</article-title>
            <source>Am J Geriatr Psychiatry</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>22</volume>
            <issue>4</issue>
            <fpage>321</fpage>
            <page-range>321-31</page-range>
            <pub-id pub-id-type="pmid">24016844</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22504.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Soares-Weiser</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fernandez</surname>
                <given-names>HH</given-names>
              </name>
            </person-group>
            <article-title>Tardive dyskinesia.</article-title>
            <source>Semin Neurol</source>
            <year>2007</year>
            <month>Apr</month>
            <volume>27</volume>
            <issue>2</issue>
            <fpage>159</fpage>
            <page-range>159-69</page-range>
            <pub-id pub-id-type="pmid">17390261</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22504.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ricciardi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pringsheim</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Barnes</surname>
                <given-names>TRE</given-names>
              </name>
              <name>
                <surname>Martino</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gardner</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Remington</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Addington</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Morgante</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Poole</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Carson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Treatment Recommendations for Tardive Dyskinesia.</article-title>
            <source>Can J Psychiatry</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>64</volume>
            <issue>6</issue>
            <fpage>388</fpage>
            <page-range>388-399</page-range>
            <pub-id pub-id-type="pmid">30791698</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22504.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Janus</surname>
                <given-names>SIM</given-names>
              </name>
              <name>
                <surname>Reinders</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>van Manen</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Zuidema</surname>
                <given-names>SU</given-names>
              </name>
              <name>
                <surname>IJzerman</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Psychotropic Drug-Related Fall Incidents in Nursing Home Residents Living in the Eastern Part of The Netherlands.</article-title>
            <source>Drugs R D</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>17</volume>
            <issue>2</issue>
            <fpage>321</fpage>
            <page-range>321-328</page-range>
            <pub-id pub-id-type="pmid">28389998</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22504.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Remelli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bugada</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Matteucci</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Brunori</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gianotti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zurlo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Volpato</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>An unwanted reaction by the use of Haloperidol in hyperkinetic delirium.</article-title>
            <source>Aging Clin Exp Res</source>
            <year>2021</year>
            <month>May</month>
            <volume>33</volume>
            <issue>5</issue>
            <fpage>1409</fpage>
            <page-range>1409-1411</page-range>
            <pub-id pub-id-type="pmid">32671642</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22504.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reznik</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Loewenthal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kotler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Apter</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Mester</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Weizman</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Granulocytopenia associated with neuroleptic therapy in a patient with benign familial leukopenia.</article-title>
            <source>Int J Psychiatry Clin Pract</source>
            <year>2003</year>
            <volume>7</volume>
            <issue>4</issue>
            <fpage>277</fpage>
            <page-range>277-80</page-range>
            <pub-id pub-id-type="pmid">24930415</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22504.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patteet</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Morrens</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maudens</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Niemegeers</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sabbe</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Neels</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic drug monitoring of common antipsychotics.</article-title>
            <source>Ther Drug Monit</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>34</volume>
            <issue>6</issue>
            <fpage>629</fpage>
            <page-range>629-51</page-range>
            <pub-id pub-id-type="pmid">23149440</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22504.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wongveerasin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Othong</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pinchumponsang</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hungspruke</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Jongjaroenwit</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Clinical Presentation and Management of Acute Dystonia from Drug Abuse or Misuse in Adolescents and Young Adults: A Retrospective Cohort Study in Bangkok, Thailand.</article-title>
            <source>Emerg Med Int</source>
            <year>2023</year>
            <volume>2023</volume>
            <fpage>2725974</fpage>
            <pub-id pub-id-type="pmid">37057297</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22504.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stroup</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Gray</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Management of common adverse effects of antipsychotic medications.</article-title>
            <source>World Psychiatry</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>17</volume>
            <issue>3</issue>
            <fpage>341</fpage>
            <page-range>341-356</page-range>
            <pub-id pub-id-type="pmid">30192094</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22504.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Solmi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Murru</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pacchiarotti</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Undurraga</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Veronese</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fornaro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stubbs</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Monaco</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Vieta</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Seeman</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Correll</surname>
                <given-names>CU</given-names>
              </name>
              <name>
                <surname>Carvalho</surname>
                <given-names>AF</given-names>
              </name>
            </person-group>
            <article-title>Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review.</article-title>
            <source>Ther Clin Risk Manag</source>
            <year>2017</year>
            <volume>13</volume>
            <fpage>757</fpage>
            <page-range>757-777</page-range>
            <pub-id pub-id-type="pmid">28721057</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
